Drugs / HU6
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07170189 | Oct → Dec 2025 | obesity disorder | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06486558 | Jul → Nov 2024 | — | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06325930 | Mar → May 2024 | — | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05433506 | Sep 2022 → Jan 2023 | obesity disorder | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT07491458 | Feb 2026 → Feb 2027 expected | metabolic dysfunction-associated steatohepatitis | Rivus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06104358 | Nov 2023 → Feb 2025 | obesity disorder, type 2 diabetes mellitus | Rivus Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05979779 | Sep 2023 → Jan 2025 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Rivus Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05284617 | Oct 2022 → May 2024 | diastolic heart failure | Rivus Pharmaceuticals, Inc. | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT04709913 Comparator | Jan → Apr 2021 | metabolic dysfunction-associated steatohepatitis | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04463017 Comparator | Aug 2020 → Mar 2021 | metabolic dysfunction-associated steatohepatitis | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04874233 Comparator | Apr → Nov 2021 | metabolic dysfunction-associated steatohepatitis | Rivus Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HU6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05284617 ↗ |
| Route | Oral | “by oral administration” PMID 37806314 ↗ Oct 2023 |